Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Clinical trial NCT04781686 · UNKNOWN

Trial details

NCT number: NCT04781686
Sponsor: Zhou Fuxiang
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Gastric Adenocarcinoma Metastatic Gastroesophageal Junction Adenocarcinoma

Start date: 2021-05-14
Primary completion: 2024-08-01
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.